Skip to content
LATEST
Markets

Nektar Therapeutics CEO sells $15,379 in shares to cover taxes

Howard Robin sold 429 shares to cover vesting taxes as the biotechnology company preserves $952.9 million in cash to fund pipeline trials through 2028.

Nektar Therapeutics CEO sells $15,379 in shares to cover taxes

Nektar Therapeutics Chief Executive Howard W. Robin sold 429 common shares for $15,379 on Nov. 17 to satisfy tax obligations from vested restricted stock units, according to a regulatory filing.

The non-discretionary transaction occurred as the stock traded near its 52-week low of $32.51 following a week-long slide of nearly 13%, even after third-quarter adjusted losses narrowed to $1.63 a share.

Robin executed the sales at prices ranging between $35.57 and $36.31, reflecting a volume-weighted average price of $35.85, according to a Form 4 filed with the Securities and Exchange Commission on Nov. 19. The disposal leaves Robin with direct ownership of 54,198 common shares, alongside 28 shares held indirectly through his spouse.

The biotechnology firm, with a market capitalisation of $1.18 billion, recently reported third-quarter revenue of $9.39 million, missing analyst projections of $10.31 million despite adjusted per-share results beating consensus expectations of negative $2.08.

Nektar closed the quarter with approximately $952.9 million in cash and investments, extending its projected operational runway into the third quarter of 2028. The reserves support Phase 3 trials of REZPEG in atopic dermatitis and alopecia areata, including initial data from the ZENITH AD trial expected in summer 2028.

Source: Form 4 securities filing, Investing.com, Nov. 20, 2026

More stories

Latest news